In this study, the formation of caffeine/dapsone (CAF/DAP) cocrystals by scalable production methods, such as liquid-assisted grinding (LAG) and spray drying, was investigated in the context of the potential use of processed cocrystal powder for pulmonary delivery. A CAF/DAP cocrystal (1:1 M ratio) was successfully prepared by slow evaporation from both acetone and ethyl acetate. Acetone, ethyl acetate, and ethanol were all successfully used to prepare cocrystals by LAG and spray drying. The powders obtained were characterized by X-ray diffractometry (XRD), differential scanning calorimetry (DSC), thermogravimetry (TGA), and Fourier transform infrared spectroscopy (FTIR). Laser diffraction analysis indicated a median particle size (D50) for spray-dried powders prepared from acetone, ethanol, and ethyl acetate of 5.4 ± 0.7, 5.2 ± 0.1, and 5.1 ± 0.0 μm respectively, which are appropriate sizes for pulmonary delivery by means of a dry powder inhaler. The solubility of the CAF/DAP cocrystal in phosphate buffer pH 7.4, prepared by spray drying using acetone, was 506.5 ± 31.5 μg/mL, while pure crystalline DAP had a measured solubility of 217.1 ± 7.8 μg/mL. In vitro cytotoxicity studies using Calu-3 cells indicated that the cocrystals were not toxic at concentrations of 0.1 and of 1 mM of DAP, while an in vitro permeability study suggested caffeine may contribute to the permeation of DAP by hindering the efflux effect. The results obtained indicate that the CAF/DAP cocrystal, particularly when prepared by the spray drying method, represents a possible suitable approach for inhalation formulations with applications in pulmonary pathologies.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, et al. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci. 2014;9:304–16.
Lipert MP, Roy L, Childs SL, Rodríguez-Hornedo N. Cocrystal solubilization in biorelevant media and its prediction from drug solubilization. J Pharm Sci. 2015;104:4153–63.
Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm. 2013;453:101–25.
Patil SP, Modi SR, Bansal AK. Generation of 1:1 carbamazepine:nicotinamide cocrystals by spray drying. Eur J Pharm Sci. 2014;62:251–7.
European Medicines Agency. Reflection paper on the use of cocrystals of active substances in medicinal products. 2015.
Karagianni A, Malamatari M, Kachrimanis K. Pharmaceutical cocrystals: new solid phase modification approaches for the formulation of APIs. Pharmaceutics [Internet]. 2018 [cited 2018 May 1];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874831/.
Food and Drug Administration. Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry. 2016.
Aitipamula S, Banerjee R, Bansal AK, Biradha K, Cheney ML, Choudhury AR, et al. Polymorphs, salts, and cocrystals: what’s in a name? Cryst Growth Des. 2012;12:2147–52.
Shan N, Zaworotko MJ. The role of cocrystals in pharmaceutical science. Drug Discov Today. 2008;13:440–6.
Kim S, Li Z, Tseng Y-C, Nar H, Spinelli E, Varsolona R, et al. Development and characterization of a cocrystal as a viable solid form for an active pharmaceutical ingredient. Org Process Res Dev. 2013;17:540–8.
Thipparaboina R, Kumar D, Chavan RB, Shastri NR. Multidrug co-crystals: towards the development of effective therapeutic hybrids. Drug Discov Today. 2016;21:481–90.
Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci. 2011;100:2172–81.
Lu J, Rohani S. Synthesis and preliminary characterization of sulfamethazine-theophylline co-crystal. J Pharm Sci. 2010;99:4042–7.
Korotkova EI, Kratochvíl B. Pharmaceutical cocrystals. Procedia Chem. 2014;10:473–6.
Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: an overview. Int J Pharm. 2011;419:1–11.
Braga D, Maini L, Grepioni F. Mechanochemical preparation of co-crystals. Chem Soc Rev. 2013;42:7638–48.
Alhalaweh A, Velaga SP. Formation of cocrystals from stoichiometric solutions of incongruently saturating systems by spray drying. Cryst Growth Des. 2010;10:3302–5.
Paudel A, Worku ZA, Meeus J, Guns S, Van den Mooter G. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int J Pharm. 2013;453:253–84.
Edwards JS, Betts L, Frazier ML, Pollet RM, Kwong SM, Walton WG, et al. Molecular basis of antibiotic multiresistance transfer in Staphylococcus aureus. Proc Natl Acad Sci U S A. 2013;110:2804–9.
Carvalho TC, Peters JI, Williams RO. Influence of particle size on regional lung deposition—what evidence is there? Int J Pharm. 2011;406:1–10.
Hickey AJ, Misra A, Fourie PB. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis. J Pharm Sci. 2013;102:3900–7.
Mukker JK, Singh RSP, Derendorf H. Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy. Adv Drug Deliv Rev. 2015;85:57–64.
Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74.
Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices Auckl. 2015;8:131–9.
Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci. 2010;99:1–20.
Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev. 1996;19:3–36.
Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1:338–44.
Yang MY, Chan JGY, Chan H-K. Pulmonary drug delivery by powder aerosols. J Control Release. 2014;193:228–40.
Jones RM, Neef N. Interpretation and prediction of inhaled drug particle accumulation in the lung and its associated toxicity. Xenobiotica. 2012;42:86–93.
Cochrane RG, Ramanujam K, Paul H, Russell D. Two-and-a-half years’ experimental work on the sulphone group of drugs. Lepr Rev. 1949;20:4–64.
Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol JDD. 2007;6:981–7.
Pickert A, Raimer S. An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009;10:1515–21.
Wozel VEG. Innovative use of dapsone. Dermatol Clin. 2010;28:599–610.
Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306:103–24.
Lee KH, Park JH, Kim DH, Hwang J, Lee G, Hyun JS, et al. Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP). Med Hypotheses. 2017;108:42–5.
Grebogi IH, Tibola APOV, Barison A, Grandizoli CWPS, Ferraz HG, Rodrigues LNC. Binary and ternary inclusion complexes of dapsone in cyclodextrins and polymers: preparation, characterization and evaluation. J Incl Phenom Macrocycl Chem. 2012;73:467–74.
Dhople AM. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae. Int J Antimicrob Agents. 1999;12:319–23.
Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1–207. quiz CE1–2074
Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis. 1998;27:191–204.
Agrawal S, Agarwalla A. Dapsone hypersensitivity syndrome: a clinico-epidemiological review. J Dermatol. 2005;32:883–9.
Gutiérrez S, Morilla R, León JA, Martín-Garrido I, Rivero L, Friaza V, et al. High prevalence of pneumocystis jiroveci colonization among young HIV-infected patients. J Adolesc Health. 2011;48:103–5.
Nickel S, Clerkin CG, Selo MA, Ehrhardt C. Transport mechanisms at the pulmonary mucosa: implications for drug delivery. Expert Opin Drug Deliv. 2016;13:667–90.
Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265–78.
Martins I, Martins M, Fernandes A, André V, Duarte MT. An insight into dapsone co-crystals: sulfones as participants in supramolecular interactions. CrystEngComm. 2013;15:8173–9.
He H, Jiang L, Zhang Q, Huang Y, Wang J-R, Mei X. Polymorphism observed in dapsone–flavone cocrystals that present pronounced differences in solubility and stability. CrystEngComm. 2015;17:6566–74.
Jiang L, Huang Y, Zhang Q, He H, Xu Y, Mei X. Preparation and solid-state characterization of dapsone drug–drug co-crystals. Cryst Growth Des. 2014;14:4562–73.
Kassim Z, Greenough A, Rafferty GF. Effect of caffeine on respiratory muscle strength and lung function in prematurely born, ventilated infants. Eur J Pediatr. 2009;168:1491–5.
Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam. 2003;20:1–30.
Grossjohann C, Serrano DR, Paluch KJ, O’Connell P, Vella-Zarb L, Manesiotis P, et al. Polymorphism in sulfadimidine/4-aminosalicylic acid cocrystals: solid-state characterization and physicochemical properties. J Pharm Sci. 2015;104:1385–98.
Healy A. Cocrystal habit engineering to improve drug dissolution and alter derived powder properties. 2016 [cited 2017 Nov 14]; Available from: http://www.tara.tcd.ie/handle/2262/78793.
Nie J, Yang D, Hu K, Lu Y. Study on four polymorphs of bifendate based on X-ray crystallography. Acta Pharm Sin B. 2016;6:234–42.
Amaro MI, Tewes F, Gobbo O, Tajber L, Corrigan OI, Ehrhardt C, et al. Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. Int J Pharm. 2015;483:6–18.
Paluch KJ, Tajber L, Corrigan OI, Healy AM. Impact of process variables on the micromeritic and physicochemical properties of spray-dried porous microparticles, part I: introduction of a new morphology classification system. J Pharm Pharmacol. 2012;64:1570–82.
de Almeida Borges VR, Simon A, Sena ARC, Cabral LM, de Sousa VP. Nanoemulsion containing dapsone for topical administration: a study of in vitro release and epidermal permeation. Int J Nanomedicine. 2013;8:535–44.
Harris KDM, Cheung EY. How to determine structures when single crystals cannot be grown: opportunities for structure determination of molecular materials using powder diffraction data. Chem Soc Rev. 2004;33:526–38.
Corrigan OI. Thermal analysis of spray dried products. Thermochim Acta. 1995;248:245–58.
Serrano DR, Persoons T, D’Arcy DM, Galiana C, Dea-Ayuela MA, Healy AM. Modelling and shadowgraph imaging of cocrystal dissolution and assessment of in vitro antimicrobial activity for sulfadimidine/4-aminosalicylic acid cocrystals. Eur J Pharm Sci. 2016;89:125–36.
Amaro MI, Tajber L, Corrigan OI, Healy AM. Optimisation of spray drying process conditions for sugar nanoporous microparticles (NPMPs) intended for inhalation. Int J Pharm. 2011;421:99–109.
Cal K, Sollohub K. Spray drying technique. I: hardware and process parameters. J Pharm Sci. 2010;99:575–86.
Chikhalia V, Forbes RT, Storey RA, Ticehurst M. The effect of crystal morphology and mill type on milling induced crystal disorder. Eur J Pharm Sci. 2006;27:19–26.
Wang W, Zhou QT, Sun S-P, Denman JA, Gengenbach TR, Barraud N, et al. Effects of surface composition on the aerosolisation and dissolution of inhaled antibiotic combination powders consisting of colistin and rifampicin. AAPS J. 2016;18:372–84.
Healy AM, Amaro MI, Paluch KJ, Tajber L. Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Deliv Rev. 2014;75:32–52.
Walsh D, Serrano DR, Worku ZA, Norris BA, Healy AM. Production of cocrystals in an excipient matrix by spray drying. Int J Pharm. 2018;536:467–77.
Foster KA, Avery ML, Yazdanian M, Audus KL. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm. 2000;208:1–11.
Matilainen L, Toropainen T, Vihola H, Hirvonen J, Järvinen T, Jarho P, et al. In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J Control Release. 2008;126:10–6.
Ong HX, Traini D, Young PM. Pharmaceutical applications of the Calu-3 lung epithelia cell line. Expert Opin Drug Deliv. 2013;10:1287–302.
Ortiz M, Jornada DS, Pohlmann AR, Guterres SS. Development of novel chitosan microcapsules for pulmonary delivery of dapsone: characterization, aerosol performance, and in vivo toxicity evaluation. AAPS PharmSciTech. 2015;16:1033–40.
Seeland S, Treiber A, Hafner M, Huwyler J. On-line identification of P-glycoprotein substrates by monitoring of extracellular acidification and respiration rates in living cells. Biochim Biophys Acta BBA - Biomembr. 2011;1808:1827–31.
Chappe V, Mettey Y, Vierfond JM, Hanrahan JW, Gola M, Verrier B, et al. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br J Pharmacol. 1998;123:683–93.
Bulteau L, Dérand R, Mettey Y, Métayé T, Morris MR, McNeilly CM, et al. Properties of CFTR activated by the xanthine derivative X-33 in human airway Calu-3 cells. Am J Physiol Cell Physiol. 2000;279:C1925–37.
The authors acknowledge the assistance of Dr. Helge Müller-Bunz, School of Chemistry and Chemical Biology, University College Dublin, Ireland, in undertaking the SC-XRD analysis.
This material is based upon works supported by FAPERJ (Rio de Janeiro, Brazil), CAPES (Brasília, Brazil) under Grant No. 3372/13-8 and the Science Foundation Ireland under Grant No. 12/RC/2275.
Conflict of Interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
do Amaral, L.H., do Carmo, F.A., Amaro, M.I. et al. Development and Characterization of Dapsone Cocrystal Prepared by Scalable Production Methods. AAPS PharmSciTech 19, 2687–2699 (2018). https://doi.org/10.1208/s12249-018-1101-5
- liquid-assisted grinding
- spray drying
- dry powder inhaler